While, recently, the Merck Company announced that the REVEAL (Evaluation of the Effects of Anacetrapib through Lipid Modification) study, which studies the effects of Anacetrapib on cardiovascular disease outcome met its primary end point, significantly reducing major coronary events defined as the composite of coronary death, myocardial infarction, and coronary revascularization.15 These results illustrate that the role and underlying mechanism of CETP in cardiovascular disease pathology is more complex than initially anticipated. Here, CETP is linked to cardiovascular disorder.